预约演示
更新于：2025-05-16
Methocarbamol
美索巴莫
更新于：2025-05-16
概要
基本信息
简介以 Robaxin 等品牌名称销售的美索巴莫是一种用于治疗短期肌肉骨骼疼痛的药物。 它可以与休息、物理治疗和止痛药一起使用。 它不太适合用于腰痛。 它对类风湿性关节炎和脑瘫的使用有限。 效果通常在半小时内开始。 口服或静脉注射。 常见的副作用包括头痛、嗜睡和头晕。 严重的副作用可能包括过敏反应、肝脏问题、精神错乱和癫痫发作。 不建议在怀孕和哺乳期间使用。 由于存在受伤风险，老年患者通常应避免使用骨骼肌松弛剂。 美索巴莫是一种中枢性肌肉松弛剂。 它是如何工作的还不清楚，但它似乎不会直接影响肌肉。 |
药物类型 小分子化药 |
别名 (RS)-2-hydroxy-3-(2-methoxyphenoxy)propyl carbamate、Methocarbamol (JAN/USP/INN)、Methocarbamol for Suspension + [12] |
靶点 |
作用方式 抑制剂 |
作用机制 CA1抑制剂(碳酸酐酶I抑制剂) |
在研适应症 |
非在研适应症- |
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (1957-07-16), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C11H15NO5 |
InChIKeyGNXFOGHNGIVQEH-UHFFFAOYSA-N |
CAS号532-03-6 |
关联
17
项与 美索巴莫 相关的临床试验CTR20242833
评估受试制剂美索巴莫片（规格：500 mg）与参比制剂美索巴莫片（规格：500 mg）在健康成年受试者餐后状态下的单中心、开放、随机、单剂量、两周期、两序列、交叉生物等效性研究
CTR20242834
评估受试制剂美索巴莫片（规格：500 mg）与参比制剂美索巴莫片（规格：500 mg）在健康成年受试者空腹状态下的单中心、开放、随机、单剂量、两周期、两序列、交叉生物等效性研究
EUCTR2022-000788-30-PL
Evaluation of the effectiveness of Methocarbamol in the treatment ofspasticity in people with spinal cord injury.
100 项与 美索巴莫 相关的临床结果
登录后查看更多信息
100 项与 美索巴莫 相关的转化医学
登录后查看更多信息
100 项与 美索巴莫 相关的专利（医药）
登录后查看更多信息
744
项与 美索巴莫 相关的文献（医药）2025-04-01Nature Chemical Biology
Carbonic anhydrase inhibition ameliorates tau toxicity via enhanced tau secretion
Article
作者: Lopez, Ana ; Ureshino, Rodrigo Portes ; McEwan, William A. ; Siddiqi, Farah H. ; Keeling, Sophie ; Jeon, Hee-Yeon ; Rubinsztein, David C ; McEwan, William A ; Siddiqi, Farah H ; Rubinsztein, David C. ; Villeneuve, Julien ; Fleming, Angeleen ; Koulousakis, Philippos
Abstract:
Tauopathies are neurodegenerative diseases that manifest with intracellular accumulation and aggregation of tau protein. These include Pick’s disease, progressive supranuclear palsy, corticobasal degeneration and argyrophilic grain disease, where tau is believed to be the primary disease driver, as well as secondary tauopathies, such as Alzheimer’s disease. There is a need to develop effective pharmacological therapies. Here we tested >1,400 clinically approved compounds using transgenic zebrafish tauopathy models. This revealed that carbonic anhydrase (CA) inhibitors protected against tau toxicity. CRISPR experiments confirmed that CA depletion mimicked the effects of these drugs. CA inhibition promoted faster clearance of human tau by promoting lysosomal exocytosis. Importantly, methazolamide, a CA inhibitor used in the clinic, also reduced total and phosphorylated tau levels, increased neuronal survival and ameliorated neurodegeneration in mouse tauopathy models at concentrations similar to those seen in people. These data underscore the feasibility of in vivo drug screens using zebrafish models and suggest serious consideration of CA inhibitors for treating tauopathies.
2025-03-01LUMINESCENCE
Label‐Free Spectrofluorometric Method for Simultaneous Estimation of Methocarbamol and Aspirin in Biological and Pharmaceutical Matrices: Whiteness and Greenness Evaluation
Article
作者: Zeid, Abdallah M. ; El‐Aziz, Heba Abd
ABSTRACT:
A combination of methocarbamol and aspirin is commonly used for the treatment of acute musculoskeletal pain, such as low back and neck pain. Simultaneous analysis of these analytes in dosage forms and biofluids using rapid, sensitive, and selective methods would be highly beneficial. Herein, we report the first direct, label‐free spectrofluorometric method for simultaneously quantifying methocarbamol (MET) and aspirin (ASP) in coformulated tablets and spiked human urine. The method utilizes excitation at 274 nm with independent emission detection at 300 nm for MET and 402 nm for ASP, using methanol as the diluting solvent. The assay was rectilinear over ranges of 0.10–0.80 μg/mL for MET and 0.05–0.50 μg/mL for ASP with detection limits of 14.9 and 10.6 ng/mL for MET and ASP, respectively. The method was validated in compliance with ICH regulations. The approach was applied efficiently to assay both analytes in their tablets and spiked human urine with high % recoveries (98%–103%) and low RSD (1.7%–3.3%). In addition, the sustainability and practicality of the developed method were assessed using the RGB‐12 whiteness algorithm, indicating the whiteness of the developed method. The method's greenness was also confirmed using three greenness metrics that showed excellent eco‐friendliness of the developed method.
2025-02-07JOURNAL OF ORGANIC CHEMISTRY
Hydrogen Bond-Mediated Transition Metal-Free Alcoholysis of Primary Amides to Access Esters
Article
作者: Ren, Kuan ; Hou, Kaiping ; He, Lanfeng ; Gao, Ming ; Wang, Enhua ; Yang, Lishou ; Yang, Xiaosheng ; Zhou, Lang ; Ban, Yingguo
An efficient hydrogen bond-mediated alcoholysis of primary amides was disclosed using diethyl phosphonate (DEP) as a catalyst. In this process, a wide range of primary amides and alcohols were tested and smoothly transformed to corresponding esters in moderate to good yields. This novel strategy features transition metal-free, broad substrate scope and a hydrogen bond-mediated one-pot pathway. In addition, the reaction showed a highly chemoselective o/alcoholic o-acylation of mercapto/phenolic alcohols.
100 项与 美索巴莫 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 肌肉骨骼疼痛 | 美国 | 1957-07-16 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | 夢鑰鹽廠製積顧窪遞鏇(淵襯艱糧艱廠糧艱範餘): RR = 1.32 (95% CI, 1.19 ~ 1.44) 更多 | - | 2023-02-01 | |||
临床4期 | 153 | (Placebo Infusion) | 觸範糧餘選積憲齋選壓(餘憲鬱憲獵窪選顧鑰範) = 獵築願齋遞蓋鏇蓋淵鬱 醖顧齋齋醖鹽選簾襯淵 (製淵鏇築積醖醖鬱範憲, 2) 更多 | - | 2020-02-05 | ||
(Ketamine Infusion) | 觸範糧餘選積憲齋選壓(餘憲鬱憲獵窪選顧鑰範) = 糧襯衊製鑰願窪鹹選願 醖顧齋齋醖鹽選簾襯淵 (製淵鏇築積醖醖鬱範憲, 2.1) 更多 | ||||||
临床3期 | 80 | 襯鬱淵遞獵製顧網築膚 = 夢製鹽壓窪鑰衊網顧淵 繭夢築壓遞鹹選願網膚 (顧築鏇餘獵艱蓋蓋艱鹹, 鬱襯鹽夢構餘鏇繭襯鹽 ~ 繭壓齋鹹顧鹽選鏇蓋淵) 更多 | - | 2018-07-20 | |||
临床4期 | 240 | Placebo+Naproxen (Placebo) | 糧範餘艱鏇糧鬱艱繭廠(積鹹齋鏇餘遞憲構網鹹) = 鑰範廠鹹顧衊構鑰蓋鏇 遞憲遞壓艱襯範窪獵觸 (鬱願襯簾觸衊積繭製淵, 鬱製獵鹹積餘遞觸壓鹹 ~ 鏇製鑰構窪鹽簾夢醖範) 更多 | - | 2018-06-26 | ||
(Orphenadrine) | 糧範餘艱鏇糧鬱艱繭廠(積鹹齋鏇餘遞憲構網鹹) = 鬱鹽夢觸鏇窪繭餘遞襯 遞憲遞壓艱襯範窪獵觸 (鬱願襯簾觸衊積繭製淵, 繭膚鏇簾顧壓願遞襯築 ~ 醖遞網網獵壓膚憲獵繭) 更多 | ||||||
临床4期 | 240 | Naproxen+Placebo | 鑰網壓獵選壓艱醖糧齋(醖餘膚願願廠窪廠鑰膚) = 選鬱築鹽觸襯餘製窪膚 蓋艱糧齋鬱餘積糧簾獵 (網鏇製獵鑰選繭鹽範觸, 8.9 ~ 12.9) | 不佳 | 2018-03-01 | ||
鑰網壓獵選壓艱醖糧齋(醖餘膚願願廠窪廠鑰膚) = 鹽齋積壓製衊窪構壓蓋 蓋艱糧齋鬱餘積糧簾獵 (網鏇製獵鑰選繭鹽範觸, 7.4 ~ 11.5) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用